| Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing AJ Cole, T Dwight, AJ Gill, KA Dickson, Y Zhu, A Clarkson, GB Gard, ... Scientific reports 6 (1), 26191, 2016 | 227 | 2016 |
| Animal and translational models of SARS-CoV-2 infection and COVID-19 MD Johansen, A Irving, X Montagutelli, MD Tate, I Rudloff, MF Nold, ... Mucosal immunology 13 (6), 877-891, 2020 | 198 | 2020 |
| Histone H2B monoubiquitination: roles to play in human malignancy AJ Cole, R Clifton-Bligh, DJ Marsh Endocrine-related cancer 22 (1), T19-T33, 2015 | 130 | 2015 |
| Histones and their modifications in ovarian cancer–drivers of disease and therapeutic targets DJ Marsh, JS Shah, AJ Cole Frontiers in oncology 4, 144, 2014 | 71 | 2014 |
| CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer M Iyengar, P O’Hayer, A Cole, T Sebastian, K Yang, L Coffman, ... Oncotarget 9 (21), 15658, 2018 | 61 | 2018 |
| An evolving paradigm of cancer stem cell hierarchies: therapeutic implications AJ Cole, AP Fayomi, VI Anyaeche, S Bai, RJ Buckanovich Theranostics 10 (7), 3083, 2020 | 57 | 2020 |
| Therapeutic impact of nanoparticle therapy targeting tumor-associated macrophages CA Penn, K Yang, H Zong, JY Lim, A Cole, D Yang, J Baker, ... Molecular cancer therapeutics 17 (1), 96-106, 2018 | 54 | 2018 |
| NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer AJ Cole, M Iyengar, S Panesso-Gómez, P O’Hayer, D Chan, GM Delgoffe, ... JCI insight 5 (7), 2020 | 37 | 2020 |
| The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models … KA Dickson, AJ Cole, AJ Gill, A Clarkson, GB Gard, A Chou, CJ Kennedy, ... Human Molecular Genetics 25 (24), 5460-5471, 2016 | 34 | 2016 |
| Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs L Loo, MA Waller, CL Moreno, AJ Cole, AO Stella, OT Pop, AK Jochum, ... PLoS biology 21 (2), e3001967, 2023 | 30 | 2023 |
| Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors E Grimley, AJ Cole, TT Luong, SC McGonigal, S Sinno, D Yang, ... Theranostics 11 (8), 3540, 2021 | 26 | 2021 |
| Approaches to enhance precise CRISPR/Cas9-mediated genome editing CE Denes, AJ Cole, YA Aksoy, G Li, GG Neely, D Hesselson International journal of molecular sciences 22 (16), 8571, 2021 | 21 | 2021 |
| Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency AJ Cole, Y Zhu, T Dwight, B Yu, KA Dickson, GB Gard, J Maidens, ... Scientific data 4 (1), 1-8, 2017 | 18 | 2017 |
| Ubiquitin chromatin remodelling after DNA damage is associated with the expression of key cancer genes and pathways AJ Cole, KA Dickson, C Liddle, C Stirzaker, JS Shah, R Clifton-Bligh, ... Cellular and Molecular Life Sciences 78, 1011-1027, 2021 | 12 | 2021 |
| A miRNA-mediated approach to dissect the complexity of tumor-initiating cell function and identify miRNA-targeting drugs AB Nagaraj, P Joseph, E Ponting, Y Fedorov, S Singh, A Cole, W Lee, ... Stem Cell Reports 12 (1), 122-134, 2019 | 12 | 2019 |
| Quiescent ovarian cancer cells secrete follistatin to induce chemotherapy resistance in surrounding cells in response to chemotherapy AJ Cole, S Panesso-Gómez, JS Shah, T Ebai, Q Jiang, ... Clinical Cancer Research 29 (10), 1969-1983, 2023 | 6 | 2023 |
| Advanced pathophysiology mimicking lung models for accelerated drug discovery TH Phan, H Shi, CE Denes, AJ Cole, Y Wang, YY Cheng, D Hesselson, ... Biomaterials Research 27 (1), 35, 2023 | 6 | 2023 |
| The VEGAS platform is unsuitable for mammalian directed evolution CE Denes, AJ Cole, MTN Tran, MKN Mohd Khalid, AW Hewitt, ... ACS Synthetic Biology 11 (10), 3544-3549, 2022 | 4 | 2022 |
| Zebrafish CCNF and FUS Mediate Stress-Specific Motor Responses YA Aksoy, AJ Cole, W Deng, D Hesselson Cells 13 (5), 372, 2024 | | 2024 |
